Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management

Medicine & Life Sciences

• Systemic Mastocytosis 100%
• Risk Management 74%
• Mast Cells 33%
• Imatinib Mesylate 15%
• Mast-Cell Leukemia 11%
• Mutation 11%
• midostaurin 11%
• Cladribine 9%
• Tryptases 8%
• Molecular Models 8%
• Anaphylaxis 7%
• Allogeneic Cells 7%
• Hematologic Neoplasms 6%
• United States Food and Drug Administration 6%
• Acute Myeloid Leukemia 6%
• Cell- and Tissue-Based Therapy 6%
• Interferons 6%
• Osteoporosis 6%
• Stem Cells 5%
• Bone Marrow 4%
• Therapeutics 4%
• Transplants 4%
• Skin 3%
• Serum 3%